News & Events

1 11, 2022

Remarkable results from CAR-T cell therapy for lupus

2024-07-10T19:28:27+00:00

A recent study has shown remarkable results from compassionate use of CAR-T cell therapy to treat severe lupus in five patients in whom multiple other treatments had previously failed. CAR-T cell therapy involves genetically engineering T cells, a type of immune cell, so that they respond to a prespecified molecular marker, or antigen. This means they mount an immune response against cells with the chosen antigen...

Remarkable results from CAR-T cell therapy for lupus2024-07-10T19:28:27+00:00
26 10, 2022

Kyverna Therapeutics Submits IND for Novel CAR T-Cell Therapy to Treat Lupus Nephritis

2022-10-26T14:30:28+00:00

Company files its first Investigational New Drug application for its lead program KYV-101, a novel fully human CD19 CAR T-cell therapy, for the treatment of lupus nephritis. Kyverna’s therapeutic platform combines advanced T-cell engineering and synthetic biology technologies to suppress and eliminate...

Kyverna Therapeutics Submits IND for Novel CAR T-Cell Therapy to Treat Lupus Nephritis2022-10-26T14:30:28+00:00
18 10, 2022

A report on the state of the cell and gene therapy industry

2022-10-18T15:39:46+00:00

Twice a year, the Alliance for Regenerative Medicine (ARM) surveys the cell and gene therapy landscape and ARM’s initiatives to advance the sector and provide an update to their members, their stakeholders, and the public at large. While external conditions ebb and flow, the sector’s progress — in clinical milestones, regulatory developments, and patient impact — steadily advances...

A report on the state of the cell and gene therapy industry2022-10-18T15:39:46+00:00
11 10, 2022

Cell & Gene Meeting on the Mesa – 2022

2025-03-14T19:55:58+00:00

Avance offers a broad range of assay development services, including assay design, assay validation, sample testing, and technology transfer under GLP compliance to support IND-enabling and clinical studies. With decades of experience helping gene and cell therapy companies, Avance Biosciences™ has the...

Cell & Gene Meeting on the Mesa – 20222025-03-14T19:55:58+00:00
27 09, 2022

Biotech Boston – 2022

2025-03-14T19:57:24+00:00

Ensure the Success of Your Biological Drug Development - Avance Provides Assays to Support your Biopharmaceutical Development & Manufacturing - Avance Biosciences™ is a world-leading CRO specializing in GLP & GMP compliant biological assay development, assay validation, and [...]

Biotech Boston – 20222025-03-14T19:57:24+00:00
13 09, 2022

Kyverna Therapeutics’ $85 million series B financing reflects significant investor confidence in the science behind cell therapies

2024-07-10T19:49:38+00:00

Kyverna Therapeutics, a cell therapy company engineering a new class of therapies for serious autoimmune diseases, today announced it has closed an oversubscribed $85 million Series B financing round led by Northpond Ventures. Additional investors included the company’s founding investors Westlake Village BioPartners (“Westlake”), Vida Ventures, and Gilead Sciences (“Gilead”), with new investors RTW [...]

Kyverna Therapeutics’ $85 million series B financing reflects significant investor confidence in the science behind cell therapies2024-07-10T19:49:38+00:00
30 08, 2022

First allogeneic cell therapy candidate engineered to target cd19 for b-cell malignancies receives IND clearance, will proceed to clinical trials

2024-07-10T19:49:27+00:00

Century Therapeutics, an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, announced today that the company has been notified by the U.S. Food and Drug Administration (FDA) that the Company’s ELiPSE-1 clinical study may proceed to assess CNTY-101 in patients with relapsed or refractory CD19 positive B-cell malignancies. CNTY-101 is [...]

First allogeneic cell therapy candidate engineered to target cd19 for b-cell malignancies receives IND clearance, will proceed to clinical trials2024-07-10T19:49:27+00:00
23 08, 2022

FDA approves the first gene therapy for people with beta-thalassemia who require regular red blood cell transfusions

2024-07-10T19:27:05+00:00

bluebird bio has announced the the U.S. Food and Drug Administration (FDA) has approved ZYNTEGLO® (betibeglogene autotemcel), also known as beti-cel, a one-time gene therapy custom-designed to treat the underlying genetic cause of beta‑thalassemia in adult and pediatric patients who require regular red blood cell (RBC) transfusions. “The FDA approval of ZYNTEGLO offers people with [...]

FDA approves the first gene therapy for people with beta-thalassemia who require regular red blood cell transfusions2024-07-10T19:27:05+00:00
9 08, 2022

How gene therapy can cure or treat diseases

2024-07-10T19:31:26+00:00

The genes in your body’s cells play a key role in your health. Indeed, a defective gene or genes can make you sick. Recognizing this, scientists have worked for decades on ways to modify genes or replace faulty genes with healthy ones to treat, cure, or prevent a disease or medical condition. [...]

How gene therapy can cure or treat diseases2024-07-10T19:31:26+00:00
2 08, 2022

ARM and NIIMBL Release Project A-Cell to Bring Quality by Design Principles to Cell-Based Therapy Manufacturing

2024-07-10T19:49:08+00:00

Effort to address challenges to the manufacturing scale-up of cell-based therapies follows release of Project A-Gene for gene therapy in 2021 The Alliance for Regenerative Medicine (ARM) and the National Institute for Innovation in Manufacturing BioPharmaceuticals (NIIMBL) today released Project A-Cell, a multistakeholder collaboration to incorporate Quality by Design (QbD) principles into a manufacturing case [...]

ARM and NIIMBL Release Project A-Cell to Bring Quality by Design Principles to Cell-Based Therapy Manufacturing2024-07-10T19:49:08+00:00
Go to Top